Reality Check on Prostate Cancer
Market access for prostate cancer treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: More than 82% of the lives under the medical benefit are covered without utilization management restriction under Medicare policies
- Class Trends: The FDA granted an additional approval to Xtandi for the treatment for nonmetastatic castration-resistant prostate cancer
- Key Findings: A U.S. district court ruled that patent claims for Zytiga were invalid. Janssen said it will appeal the decision, but generic versions of the drug could launch at-risk.
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.